Dec. 22 at 11:45 AM
🚨 Bullish on
$QNCX 🚨
Listen to CEO & CMO Dirk Thye, M.D. lay out why EryDex is poised for success in Ataxia-Telangiectasia:
High dose outperforms low dose
Innovative delivery eliminates toxicity while maintaining efficacy, strong safety data
Strong biological corroboration from gene expression data + dose response
<20% expected failure rate vs. industry 50/60%>
Pivotal Phase 3 NEAT trial rigorously designed, placebo-controlled, double-blind
SPA with FDA – enables potential single trial approval
Topline data Q1 2026
This is a rare disease asset with massive potential in a brutal
$XBI environment.
Dirk's track record speaks for itself.
$QNCX undervalued and overlooked. Long and strong. 💎🙌
Also never been a reverse split. Good float.
Not financial advice. Do your own research.
#biotech #raredisease
